Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1983 3
1984 4
1985 4
1986 1
1987 1
1988 4
1989 2
1991 4
1992 2
1993 4
1994 5
1995 5
1996 9
1997 7
1998 5
1999 5
2000 16
2001 4
2002 6
2003 6
2004 9
2005 7
2006 6
2007 8
2008 9
2009 7
2010 9
2011 12
2012 12
2013 13
2014 14
2015 12
2016 14
2017 12
2018 11
2019 10
2020 18
2021 10
2022 8
2023 8
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant Peritoneal and Retroperitoneal Neoplasm"
Page 1
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD. Al-Batran SE, et al. JAMA Oncol. 2017 Sep 1;3(9):1237-1244. doi: 10.1001/jamaoncol.2017.0515. JAMA Oncol. 2017. PMID: 28448662 Free PMC article. Clinical Trial.
CONCLUSIONS AND RELEVANCE: Patients with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed a favorable survival. The AIO-FLOT3 trial provides a rationale for further randomized clinical trials. TRIAL REGIS …
CONCLUSIONS AND RELEVANCE: Patients with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed a …
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ, Pedersen KS, Park JO, Ramirez RA, Abad DG, Feliu J, Muñoz A, Ponz-Sarvise M, Peled A, Lustig TM, Bohana-Kashtan O, Shaw SM, Sorani E, Chaney M, Kadosh S, Vainstein Haras A, Von Hoff DD, Hidalgo M. Bockorny B, et al. Nat Med. 2020 Jun;26(6):878-885. doi: 10.1038/s41591-020-0880-x. Epub 2020 May 25. Nat Med. 2020. PMID: 32451495 Clinical Trial.
These data suggest that combined CXCR4 and PD-1 blockade may expand the benefit of chemotherapy in PDAC and warrants confirmation in subsequent randomized trials....
These data suggest that combined CXCR4 and PD-1 blockade may expand the benefit of chemotherapy in PDAC and warrants confirmation in subsequ …
Lymphatic manifestations of lymphangioleiomyomatosis.
Gupta R, Kitaichi M, Inoue Y, Kotloff R, McCormack FX. Gupta R, et al. Lymphology. 2014 Sep;47(3):106-17. Lymphology. 2014. PMID: 25420303 Review.
Lymphangioleiomyomatosis (LAM) is a slowly progressive, low grade, metastasizing neoplasm, associated with cellular invasion and cystic destruction of the pulmonary parenchyma. ...Lymphatic manifestations of LAM include thoracic duct wall invasion, lymphangioleiomyoma form …
Lymphangioleiomyomatosis (LAM) is a slowly progressive, low grade, metastasizing neoplasm, associated with cellular invasion and cyst …
Adrenal tumours: open surgery versus minimally invasive surgery.
Fiori C, Checcucci E, Amparore D, Cattaneo G, Manfredi M, Porpiglia F. Fiori C, et al. Curr Opin Oncol. 2020 Jan;32(1):27-34. doi: 10.1097/CCO.0000000000000594. Curr Opin Oncol. 2020. PMID: 31644473 Review.
RECENT FINDINGS: The laparoscopic (both transperitoneal and retroperitoneal) approach is the first-choice treatment in cases of small-to-medium benign adrenal tumours. ...Recent evidence suggests caution in treating localized ACC with laparoscopy, because of the higher rat …
RECENT FINDINGS: The laparoscopic (both transperitoneal and retroperitoneal) approach is the first-choice treatment in cases of small …
Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a systematic review and meta-analysis.
Fan X, Xu K, Lin T, Liu H, Yin Z, Dong W, Huang H, Huang J. Fan X, et al. BJU Int. 2013 Apr;111(4):611-21. doi: 10.1111/j.1464-410X.2012.11598.x. Epub 2012 Oct 29. BJU Int. 2013. PMID: 23106964 Review.
OBJECTIVE: To evaluate the efficiency and safety of the retroperitoneal and transperitoneal approaches in laparoscopic radical/partial nephrectomy (RN/PN) for renal cell carcinoma. ...RESULTS: Twelve studies assessing transperitoneal laparoscopic RN (TLRN) vs retroperit …
OBJECTIVE: To evaluate the efficiency and safety of the retroperitoneal and transperitoneal approaches in laparoscopic radical/partia …
Laparoscopic adrenalectomy--indications and technique.
Lal G, Duh QY. Lal G, et al. Surg Oncol. 2003 Aug;12(2):105-23. doi: 10.1016/s0960-7404(03)00036-7. Surg Oncol. 2003. PMID: 12946482 Review.
The role of laparoscopic adrenalectomy in the management of malignant adrenal tumors is controversial and most adrenocortical cancers are generally treated by open adrenalectomy. ...Although there are no randomized trials comparing laparoscopic with open adrenalecto …
The role of laparoscopic adrenalectomy in the management of malignant adrenal tumors is controversial and most adrenocortical cancers …
Diagnostic yield and safety of percutaneous CT-guided biopsy of retroperitoneal lesions and analysis of imaging features.
Singh AK, Neyaz Z, Verma R, Gupta A, Mishra R, Mishra P. Singh AK, et al. Acta Radiol. 2022 Feb;63(2):149-158. doi: 10.1177/0284185121990286. Epub 2021 Feb 2. Acta Radiol. 2022. PMID: 33530697
PURPOSE: To assess diagnostic yield and safety of CT-guided biopsy of retroperitoneal lesions and compare CT findings in different disease categories. ...Major disease categories on final diagnosis were lymphoma, tuberculosis, and metastases. A variety of malignant …
PURPOSE: To assess diagnostic yield and safety of CT-guided biopsy of retroperitoneal lesions and compare CT findings in different di …
Can lymphadenectomy be omitted in advanced ovarian cancer?-a brief review.
Salcedo-Hernández RA. Salcedo-Hernández RA. Chin Clin Oncol. 2020 Aug;9(4):46. doi: 10.21037/cco-20-35. Epub 2020 Jun 3. Chin Clin Oncol. 2020. PMID: 32527112 Free article. Review.
The indication of systematic lymphadenectomy in advanced ovarian cancer without apparent macroscopic lymph node involvement has been controversial over the past three decades, and the recommendation to perform it or not has been based on multiple retrospective studies, small coho …
The indication of systematic lymphadenectomy in advanced ovarian cancer without apparent macroscopic lymph node involvement has been controv …
Transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: A systematic review and meta-analysis.
Xia L, Zhang X, Wang X, Xu T, Qin L, Zhang X, Zhong S, Shen Z. Xia L, et al. Int J Surg. 2016 Jun;30:109-15. doi: 10.1016/j.ijsu.2016.04.023. Epub 2016 Apr 20. Int J Surg. 2016. PMID: 27107660 Free article. Review.
PURPOSE: To compare the perioperative outcomes of the transperitoneal (TP) and retroperitoneal (RP) approaches in robot-assisted partial nephrectomy (RAPN). ...Pooled odds ratios (ORs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated …
PURPOSE: To compare the perioperative outcomes of the transperitoneal (TP) and retroperitoneal (RP) approaches in robot-assisted part …
Treatment of advanced carcinoid tumors.
Lal A, Chen H. Lal A, et al. Curr Opin Oncol. 2006 Jan;18(1):9-15. doi: 10.1097/01.cco.0000198018.53606.62. Curr Opin Oncol. 2006. PMID: 16357558 Review.
RECENT FINDINGS: Recent literature has advocated for more aggressive surgical treatment of carcinoid tumors, especially in the setting of hepatic metastases and peritoneal carcinomatosis. Octreotide and lanreotide are further being described for treating metastatic carcino …
RECENT FINDINGS: Recent literature has advocated for more aggressive surgical treatment of carcinoid tumors, especially in the setting of he …
278 results